The pretest and posttest values were used as the covariate and dependent variable, respectively. When appropriate, LSD post hoc pairwise comparisons were used to examine the differences among the groups. For effect size, the partial eta squared statistic was calculated, and according to Green et al. [31], 0.01, 0.06, and 0.14 were Rho inhibitor interpreted as small, medium, and large effect sizes, respectively.
Two-way ANOVA (Time × treatment) was used to examine changes in plasma HMB concentration between PLA-HIIT and HMBFA-HIIT. Independent-samples t-tests’ find more were performed to compare total training volume, total energy and leucine intake for the PLA-HIIT and HMBFA-HIIT groups. An alpha of p < 0.05 was established a priori. Results The pre- and post-intervention mean and standard deviations for all metabolic and performance measures (VO2peak, Ppeak, Tmax, RCP, PRCP, VT, and PVT) for all groups (CTL, PLA-HIIT, HMBFA-HIIT) are provided in Table 2. Table 3 provides the group mean and standard deviations for pre- to post-intervention body composition measures (BW, LSTM, and BF). Table 2 Metabolic and performance measures for pre- and post-supplementation Control (n = 8) PLA-HIIT (n = 13) HMBFA-HIIT (n = 13) Measure Pretest Posttest Pretest Posttest Pretest Posttest VO2peak (ml · kg-1 · min-1) 39.1 ± 4.5 38.9 ± 4.0 38.9 ± 3.4 40.3 ± 2.6 39.8 ± 6.7 42.7 ± 5.1 Ppeak (W) 218.8 ± 41.7 215.6 ± 32.6 221.2 ± 46.6 236.5 ± 48.5 226.9 ± 56.3 246.2 ± 54.8
Tmax (min) 12.5 ± 2.9 12.2 ± 2.3 13.0 ± 3.8 Osimertinib research buy 14.2 ± 3.7 13.6 ± 4.7 14.9 ± 4.5 RCP (ml · kg-1 · min-1) 30.5 ± 5.0 28.7 ± 2.7 29.3 ± 3.1 31.9 ± 2.2 32.2 ± 4.2 33.7 ± 3.8 PRCP
(W) 175.3 ± 38.8 167.0 ± 24.8 168.4 ± 36.0 Telomerase 185.0 ± 33.5 182.6 ± 33.6 196.5 ± 35.1 VT (ml · kg-1 · min-1) 27.7 ± 3.3 27.2 ± 2.7 28.6 ± 3.1 29.0 ± 4.1 27.8 ± 4.8 31.7 ± 3.7 PVT (W) 156.3 ± 17.7 153.1 ± 28.2 159.6 ± 40.2 169.2 ± 37.0 161.5 ± 39.02 184.6 ± 37.6 Values are means ± SD. HIIT, high-intensity interval training; HMBFA, β-hydroxy-β-methylbutyrate in the free acid form (BetaTor™, Metabolic Technologies Inc, Ames, IA); PLA, placebo; VO2peak, peak oxygen uptake; Ppeak, peak power achieved; Tmax, time to exhaustion during graded exercise test; RCP, respiratory-compensation point; VT, ventilatory threshold. Table 3 Body composition measures for pre- and post-supplementation Control (n = 8) PLA-HIIT (n = 13) HMBFA-HIIT (n = 13) Measure Pretest Posttest Pretest Posttest Pretest Posttest Body weight (kg) 76.3 ± 12.8 75.5 ± 12.7 74.9 ± 16.6 75.2 ± 16.3 72.4 ± 9.9 72.5 ± 10.0 Lean soft tissue mass (kg) 56.5 ± 11.7 56.4 ± 10.7 58.4 ± 16.6 58.6 ± 16.6 52.2 ± 10.9 52.2 ± 10.9 Total body fat mass (kg) 15.9 ± 7.0 14.3 ± 8.4 13.3 ± 4.8 13.2 ± 4.6 16.9 ± 5.3 17.0 ± 5.4 Body fat % 22.4 ± 8.1 22.0 ± 2.8 19.7 ± 8.6 19.5 ± 8.4 24.8 ± 8.1 24.6 ± 7.7 Values are means ± SD.